Kline C Leah B, Van den Heuvel A Pieter J, Allen Joshua E, Prabhu Varun V, Dicker David T, El-Deiry Wafik S
Hematology/Oncology Division and Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033, USA. Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Hematology/Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Hematology/Oncology Division and Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033, USA.
Sci Signal. 2016 Feb 16;9(415):ra18. doi: 10.1126/scisignal.aac4374.
ONC201 (also called TIC10) is a small molecule that inactivates the cell proliferation- and cell survival-promoting kinases Akt and ERK and induces cell death through the proapoptotic protein TRAIL. ONC201 is currently in early-phase clinical testing for various malignancies. We found through gene expression and protein analyses that ONC201 triggered an increase in TRAIL abundance and cell death through an integrated stress response (ISR) involving the transcription factor ATF4, the transactivator CHOP, and the TRAIL receptor DR5. ATF4 was not activated in ONC201-resistant cancer cells, and in ONC201-sensitive cells, knockdown of ATF4 or CHOP partially abrogated ONC201-induced cytotoxicity and diminished the ONC201-stimulated increase in DR5 abundance. The activation of ATF4 in response to ONC201 required the kinases HRI and PKR, which phosphorylate and activate the translation initiation factor eIF2α. ONC201 rapidly triggered cell cycle arrest, which was associated with decreased abundance of cyclin D1, decreased activity of the kinase complex mTORC1, and dephosphorylation of the retinoblastoma (Rb) protein. The abundance of X-linked inhibitor of apoptosis protein (XIAP) negatively correlated with the extent of apoptosis in response to ONC201. These effects of ONC201 were independent of whether cancer cells had normal or mutant p53. Thus, ONC201 induces cell death through the coordinated induction of TRAIL by an ISR pathway.
ONC201(也称为TIC10)是一种小分子,可使促进细胞增殖和细胞存活的激酶Akt和ERK失活,并通过促凋亡蛋白TRAIL诱导细胞死亡。ONC201目前正处于针对各种恶性肿瘤的早期临床试验阶段。我们通过基因表达和蛋白质分析发现,ONC201通过涉及转录因子ATF4、反式激活因子CHOP和TRAIL受体DR5的综合应激反应(ISR)触发了TRAIL丰度的增加和细胞死亡。ATF4在对ONC201耐药的癌细胞中未被激活,而在对ONC201敏感的细胞中,敲低ATF4或CHOP可部分消除ONC201诱导的细胞毒性,并减少ONC201刺激的DR5丰度增加。响应ONC201时ATF4的激活需要激酶HRI和PKR,它们可磷酸化并激活翻译起始因子eIF2α。ONC201迅速触发细胞周期停滞,这与细胞周期蛋白D1丰度降低、激酶复合物mTORC1活性降低以及视网膜母细胞瘤(Rb)蛋白的去磷酸化有关。X连锁凋亡抑制蛋白(XIAP)的丰度与对ONC201的凋亡程度呈负相关。ONC201的这些作用与癌细胞的p53是正常还是突变无关。因此,ONC201通过ISR途径协同诱导TRAIL来诱导细胞死亡。